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Abstract
Tetanus as a life-threatening disease is characterized by muscle spasm. The disease is caused by the neurotoxin of Clostridium
tetani. Active form of tetanus neurotoxin is composed of the light chain (fragment A) and the heavy chain. Fragment A is a zinc
metalloprotease, which cleaves the neuronal soluble N-ethylmaleimide-sensitive attachment receptor (SNARE) protein, leading
to the blockade of inhibitory neurotransmitter release and subsequent generalizedmuscular spasm. Two functional domains of the
heavy chain are fragment C, which is required for neuronal cell binding of the toxin and subsequent endocytosis into the vesicles,
and fragment B, which is important for fragment A translocation across the vesicular membrane into the neuronal cytosol.
Currently, polyclonal immunoglobulins against tetanus neurotoxin obtained from human plasma of hyper-immunized donors
are utilized for passive immunotherapy of tetanus; however, these preparations havemany disadvantages including high lot-to-lot
heterogeneity, possibility of transmitting microbial agents, and the adverse reactions to the other proteins in the plasma.
Neutralizing anti-tetanus neurotoxin monoclonal antibodies (MAbs) lack these drawbacks and could be considered as a suitable
alternative for passive immunotherapy of tetanus. In this review, we provide an overview of the literature discussing epitope
mapping of the published neutralizing MAbs against tetanus toxin.
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Introduction
Tetanus is a bacterial infection manifesting itself by muscle
spasms. It is caused by spores of the bacterium Clostridium
tetani which exist in soil and animal intestinal tracts and con-
taminate many surfaces. These spores germinate in the anaer-
obic conditions of contaminated wounds into metabolically
active bacteria which produce tetanus neurotoxin (Thwaites
et al. 2015). The toxin prevents release of inhibitory neuro-
transmitters from neurons resulting in generalized muscular
spasms observed in tetanus. Passive protection against tetanus
toxin is obtained with polyclonal immunoglobulin prepara-
tions derived from human plasma of hyper-immunized donors
(Lang et al. 1993). Given the limitations of these preparations
(Lang et al. 1993; Kamei et al. 1990), monoclonal antibodies
(MAbs) with neutralizing capacity against tetanus might be
considered as an alternative source for passive immunothera-
py of tetanus (Kamei et al. 1990; Lang et al. 1993).
Tetanus Toxin Structure
Tetanus neurotoxin, which is produced by Clostridium tetani,
causes the life-threatening disease of tetanus. Tetanus neuro-
toxin is synthesized as a 150-kDa single polypeptide chain
and is subsequently cleaved to generate an active form of the
toxin composed of the light chain (fragment A, 50 kDa) and
the heavy chain (HC, 100 kDa), which are linked by a single
disulphide bond (Yousefi et al. 2014b). The heavy chain con-
sists of two functional domains, including the C-terminal do-
main (fragment C), which is required for neuronal cell binding
and subsequent endocytosis into vesicles, and the N-terminal
domain (fragment B), which is important for translocation of
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fragment A across the vesicular membrane into the neuronal
cytosol (Scott et al. 2010). Fragment C contains two
subdomains, including the C-terminal sub-domain of HC
(HCC) and the N-terminal sub-domain of HC (HCN). HCC
is responsible for binding of the toxin to target cells (Fig. 1)
(Yousefi et al. 2014a). Although the exact molecular mecha-
nism for tetanus toxin entrance to the neurons is unknown,
however, a dual receptors mechanism has been proposed,
which includes a gangliosides receptor especially from
GT1b and GD1b molecules and a protein receptor (Lalli
et al. 1999; Chen et al. 2009; Petrusic et al. 2012).
Fragment A as a zinc metalloprotease cleaves vesicle-
associated membrane protein-2 (VAMP-2), which is a neuronl
soluble N-ethylmaleimide-sensitive attachment receptor
(SNARE) protein, and therefore prevents release of inhibitory
neurotransmitters such as glycine and gamma-aminobutyric
acid (GABA). Furthermore, it has been shown that tetanus
toxin inhibits neurotransmitter release by activation of neuro-
nal transglutaminase (Ashton et al. 1995). Inhibition of neu-
rotransmitters release leads to a spastic paralysis observed in
tetanus (Petrusic et al. 2012).
Passive Immunotherapy of Tetanus
Humoral immunity provides protection against tetanus.
Neutralizing antibodies bind to the toxin through variable re-
gions and interfere with the attachment of the toxin to its
receptors on the target cells and subsequent internalization to
the cells (Pincus et al. 2014).
Passive immunotherapy with polyclonal immunoglobulins
obtained from human plasma of hyper-immunized donors has
been efficiently used for the prevention and therapy of tetanus
(Lang et al. 1993). However, these preparations have many
disadvantages, including high cost, the need to immunize do-
nors, lot-to-lot heterogeneity, possibility of transmitting mi-
crobial agents, and the adverse reactions to the other proteins
in the plasma (Lang et al. 1993; Kamei et al. 1990).
Monoclonal antibodies (MAbs) against tetanus toxin lack
the major drawbacks mentioned above and therefore might
be considered as an alternative for passive immunotherapy
(Kamei et al. 1990; Lang et al. 1993) (Table 1). Monoclonal
antibodies could be generated from the murine origin by hy-
bridoma technique or modified to chimeric and humanized
forms by recombinant DNA technology or produced as fully
human MAbs. Murine MAbs are not therapeutically as desir-
able as chimeric and human MAbs, due to elicitation of the
human antibody response against the immunogenic murine
epitopes leading to their inactivation and rapid clearance from
circulation. Chimeric antibodies contain murine variable re-
gions fused to human constant regions; this reduces immuno-
genicity of the chimeric antibodies in human. Humanized an-
tibodies are generated by grafting hypervariable regions of
murine antibodies on framework regions of human antibodies,
resulting in a molecule of approximately 95% human origin
(Arunachalam et al. 1992). Tetanus toxin is a large molecule
which consists of different domains. This theoretically means
that a large number of epitopes in the structure of the toxin
would be able to elicit humoral immune response.
Accordingly, it has been experimentally shown that a wide
range of MAbs against different epitopes of tetanus toxoid
can be isolated from a single individual or an animal model
(Volk et al. 1984; Lang et al. 1993). Volk et al. isolated at least
20 hybridomas producing MAbs against distinct epitopes lo-
cated on tetanus toxoid (Volk et al. 1984). In spite of genera-
tion of a wide variety of anti-tetanusMAbs in a single subject,
only a small fraction of them are able to protect against tetanus
toxin. For example, Volk et al. produced 32 MAbs against
tetanus toxin, fragment B-ΙΙb (corresponding to fragment C)
and fragment Ιbc (corresponding to fragment AB which con-
sists of both fragment A and B), while only 9 of them gave a
protection against lethal challenge of the toxin in mice (Volk
et al. 1984). Similarly, in another study, only 6 of 100 anti-
Fig. 1 Tetanus toxin structure. a Schematic representation: tetanus toxin
contains two chains including the light chain (fragment A) and the heavy
chain. The heavy chain consists of two functional domains, including
fragment C, which is required for neuronal cell binding and fragment
B, which is responsible for translocation of fragment A across the
vesicular membrane into the cytosol. Fragment C is composed of two
subdomains, including HCC and HCN. HCC contributes in the binding
of the toxin to neurons. b Three-dimensional structure (adapted from
Thwaites et al. 2015)
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tetanus MAbs showed a protective capacity against tetanus
(Lang et al. 1993). We have recently generated a panel of 22
mouse hybridoma clones specific for tetanus toxin, but only 3
of the MAbs displayed toxin neutralizing activity in an animal
model (Yousefi et al. 2014a; Yousefi et al. 2014b; Yousefi
et al. 2016). Therefore, it seems necessary to determine which
epitopes of tetanus toxin are able to elicit protective
antibodies.
Protective Epitopes Located on Fragment C
of Tetanus Toxin
Generally, protective antibodies against toxins are considered
to have neutralization capacity. In this regard, antibody-
mediated neutralization of the toxin is dependent on the ability
of the antibody to bind to the toxin and inhibits the attachment
of toxin to its cellular receptors and thereby preventing the
toxin from cellular entrance and subsequent pathological ef-
fects. Therefore, we can assume that MAbs directed against
epitopes located on fragment C, which harbors receptor bind-
ing domain of tetanus toxin, have the ability to neutralize the
toxin. In this context, blocking the receptor binding site of the
toxin by its absorption to GT1b, GD1b, and GM1 ganglio-
sides results in loss of neutralizing capacity of anti-tetanus
toxin MAbs in animal models (Petrusic et al. 2012).
Recently, we established a MAb designated 1F3B3, against
fragment A of the toxin, which was not able to inhibit the
binding of tetanus toxin to GT1b gangliosides and failed to
neutralize tetanus toxin in an animal model (Yousefi et al.
2014b). Results of another study showed that almost 42% of
anti-fragment C MAbs, which were isolated from the spleen
of the mice immunized with tetanus toxoid, were able to pro-
tect BALB/c mice from L+/1000 dose of the toxin (Volk et al.
1984), the smallest quantity of the toxin that when mixed with
0.001 IU of anti-toxin antibody causes the death of the test
animals within 96 h (Council of Europe 2010). Interestingly,
when fragment C instead of the whole toxin was used to im-
munize mice, approximately 13% of anti-fragment C MAbs
Table 1 Major features of reported tetanus toxin neutralizing monoclonal antibodies
MAb clone MAb
species
Immunizing
antigen
Toxin dose
used in mice
MAb dose used for
toxin neutralization
in mice
Epitope
recognized
by MAb
Isotype
of MAb
Affinity
of MAb
Reference
number
7-T, 16-T Mouse Tetanus toxoid L+/1000 0.32 μg Fragment B-Ιbc IgG2a NI 12
9-T, 26-T Mouse Tetanus toxoid L+/1000 3.2 μg Fragment B-Ιbc IgG1 NI 12
11-T, 17-T, 22-T Mouse Tetanus toxoid L+/1000 3.2 μg Fragment B-Ιbc IgG2a NI 12
52-T Mouse Tetanus toxoid L+/1000 3.2 μg Fragment B IgG2b NI 12
56-T Mouse Tetanus toxoid L+/1000 3.2 μg Fragment B IgG1 NI 12
19-B-ΙΙb Mouse Fragment B-ΙΙb
(fragment C)
L+/1000 3.2 μg Fragment B-ΙΙb IgG1 NI 12
TT03 Rat Tetanus toxoid L+/1000 NI Fragment C IgG1 NI 16
TT10 Rat Tetanus toxoid L+/1000 NI Fragment C IgG1 NI 16
TT06 Rat Tetanus toxoid L+/1000 NI Fragment C IgG1 NI 16
TT09 Rat Tetanus toxoid L+/1000 NI Fragment C IgG1 NI 16
G2 Human Tetanus toxoid 20 MLD 0.089 μg Fragment C NI 11 × 1010 M−1 17
G1 Human Tetanus toxoid 20 MLD 0.89 μg Fragment B NI 8.3 × 1010 M−1 17
G3 Human Tetanus toxoid 20 MLD 2.8 μg Fragment B NI 2.9 × 1010 M−1 17
G6 Human Tetanus toxoid 20 MLD 0.028 μg Fragment B NI 10 × 1010 M−1 17
G4 Human Tetanus toxoid 20 MLD 2.8 μg Fragment A NI 14 × 1010 M−1 17
F5/S/8E10 Human Tetanus toxoid 500 LD50 16.8 ng NI IgG NI 11
143 Human Tetanus toxoid L+/1000 NI Fragment C IgG1 NI 15
147 Human Tetanus toxoid L+/1000 NI Fragment C IgG1 NI 15
ST15 Human Tetanus toxoid 450 MLD NI Fragment A and
fragment C
IgG1 5.6 × 109 9
1F2C2 Mouse Tetanus toxoid 10 MLD 10 μg Fragment C IgG2a 7.1 × 108 3
1F1E12 Mouse Tetanus toxoid 10 MLD 10 μg Fragment C IgG2a 8.1 × 108 3
1F2C8 Mouse Tetanus toxoid 10 MLD 10 μg Fragment C IgG2a 1.9 × 109 3
51 Mouse Tetanus toxoid 2 LD50 10 μg Light chain IgG1 2.4 × 108 19
L+/1000 the smallest quantity of the toxin that when mixed with 0.001 IU of anti-toxin antibody causes the death of the test animals within 96 h,MLD
minimal lethal dose of the toxin, LD50 the smallest quantity of the toxin, that when administered by the specified route, causes the death of 50% of the
test animals within a given period, NI not identified
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were able to protect the mice against a dose of L+/1000 of the
toxin. These results suggest that three-dimensional structure
of fragment C, which has been enzymatically digested, might
be slightly different from that of the intact toxin. Therefore,
some antibodies generated against epitopes within the isolated
fragment C were not able to bind to the epitopes in the intact
fragment C region within the whole toxin and consequently
could not neutralize its toxic effect (Volk et al. 1984).
In another study, epitope mapping of two human anti-
tetanus toxin MAbs, which could individually protect the
mice from either paralysis or death against L+/1000 dose of
the toxin within 4 days, showed that both MAbs recognized
epitopes in fragment C and inhibited its binding to GT1b
receptors. These MAbs recognized two distinct epitopes of
fragment C, suggesting that at least two different epitopes of
fragment C are involved in the tetanus toxin binding to GT1b
receptors and blocking any of these two epitopes would confer
protection against tetanus toxin. Furthermore, by comparison
with the WHO international reference preparation of anti-
tetanus toxin, the protective activity of these MAbs was esti-
mated between 100 and 120 international units (IU) per mil-
ligram (mg) of antibody (Gustafsson et al. 1993). Results of
another study conducted by Sheppard et al. were in line with
the previous one, showing that there is at least two protective
epitopes in fragment C. Four generated MAbs in this study
recognized two dist inct epitopes of fragment C,
designatedTT03-TT10 and TT06-TT09, as appeared from
the results of competition ELISA; these MAbs were able to
protect the mice against lethal challenge of the toxin
(Sheppard et al. 1984). MAb TT04, which recognized the
third epitope of fragment C, could not protect the animals
from the lethal effect of the toxin, explaining that not all epi-
topes located in fragment C can trigger production of neutral-
izing antibodies. Two other MAbs (TT05-TT08) moderately
inhibited binding of labeledMAb TT03 andMAb TT10 to the
toxin, suggesting that their targeted epitope is in close prox-
imity to that of TT03-TT10; however, none of them reacted
with either isolated heavy or light chain of the toxin. This may
indicate that both MAbs are directed against the conforma-
tional epitopes presented on the intact molecule (Sheppard
et al. 1984). MAb-G2 is another anti-tetanus MAb generated
by Matsuda et al. and is one of the so far reported MAbs with
the highest neutralizing activity. The MAb recognizes an epi-
tope located on fragment C and can rescue the mice from
tetanus with a minimum dose of 0.089 μg in an in vitro neu-
tralization test in which 20 MLD of tetanus toxin was incu-
bated with the antibody, and the mixture was intramuscularly
injected to animals (Matsuda et al. 1992).
Anti-tetanus toxin MAbs are useful tools in exploring rela-
tionship between tetanus toxin structure and function. In order
to further characterize GT1b binding site of fragment C, 13
MAbs, all recognizing epitopes located on fragment C, were
generated by Shapiro et al. Eight MAbs which completely
inhibited biotin-labeled recombinant fragment C binding to
immobilized ganglioside GT1b, recognized overlapping epi-
topes defined as epitope 1. Sequencing of variable region
genes demonstrated that the variable region of heavy chain
(VH) and kappa light chain (Vk) of all these MAbs belonged
to VHQ52N and Vκ12/13 family, respectively. On the con-
trary, two other MAbs including 35F7 and 18.2.12.6, which
had the same VH and Vκ families (VHJ558 family and Vκ9A
family), did not compete with each other in binding to recom-
binant fragment C in a competition ELISA, suggesting that
they recognized distinct epitopes of fragment C. Interestingly,
they exerted opposite effect on the binding of fragment C to
ganglioside GT1b. While MAb 35F7 completely inhibited
binding of fragment C to ganglioside GT1b, MAb 18.2.12.6
enhanced its binding. This enhancement might be due to a
conformational change in the structure of fragment C upon
antibody binding, facilitating its binding to the gangliosides.
In other words, MAbs utilizing the same VH and VL families
in their variable region genes may not bind to the same epi-
tope. The epitopes recognized by MAbs 35F7 and 18.2.12.6
were designated epitope 2 and 3, respectively. Three other
MAbs generated in this study, including 72B9, 81H10, and
18.1.7 recognized overlapping epitopes based on the results of
competition ELISA. In spite of recognizing overlapping epi-
topes, only two of three MAbs (81H10 and 18.1.7) which
utilized VH36-60 and Vκ19/28 gene families were able to
inhibit binding of fragment C to GT1b gangliosides. Thus,
the epitope recognized by these MAbs were designated epi-
tope 4. In spite of the ability of MAbs 81H10 and 18.1.7 in
abolishing the binding of fragment C to gangliosides either
completely for 81H10 (complete abolished binding of frag-
ment C at concentration of 2.5 μg/ml) or partially for 18.1.7
(complete abolished binding of fragment C at concentration of
20 μg/ml), MAb 72B9 did not block fragment C’s binding to
gangliosides. The difference in inhibiting the binding of frag-
ment C to GT1b gangliosides between 18.1.7 and 81H10 may
be partly explained by the fusion partner utilized to immortal-
ize hybridoma 18.1.7. It was P3-X63Ag8 myeloma which
expresses endogenous IgG1,κ antibody. Therefore, the anti-
bodies generated from this hybridoma are a mixture of the
endogenous antibody and specific antibody (18.1.7), and con-
sequently, more concentrations of the MAb are required to
achieve complete inhibition of fragment C binding.
MAb72B9 used Vκ4/5 family, which was different from that
of MAbs 81H10 and 18.1.7, and it recognized a distinct epi-
tope of fragment C designated epitope 5. It is probable that this
epitope was too close to targeted epitope of MAbs 81H10 and
18.1.7 which was distinguished by a competition ELISA.
Altogether, these data suggest that at least three distinct epi-
topes of fragment C are involved in forming GT1b ganglio-
side binding site of the toxin; however, no in vivo experiment
was performed to determine the neutralizing potency of these
MAbs. In vivo experiments might help to identify whether
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different epitopes of fragment C which participate in tetanus
toxin binding to GT1b gangliosides receptors have the same
pattern of receptor binding and toxin neutralization. These
experimental data have shown that 3 sets of assays, including
competition assay, functional assay, and determining VH and
VL families, should be performed to define whether distinct or
the same/overlapping epitopes are recognized by a set of the
MAbs (Fitzsimmons et al. 2000).
Six out of 7 anti-fragment C antibodies generated in the
study of Yousefi et al. inhibited tetanus toxin binding to
GT1b gangliosides either completely (1F3E3, 1F2C2,
1F1E12, and 1F2C8) or partially (2C9B6 and 3B3D9).
Results of the in vivo neutralization study showed that
MAb 1F3E3, which displayed the highest inhibitory activ-
ity in GT1b binding assay, was not able to neutralize the
toxin in mice. Three other fragment C specific MAbs in-
cluding 1F2C2, 1F1E12, and 1F2C8 were completely able
to neutralize the toxin, whereas 2C9B6 and 3B3D9 MAbs
only resulted in a partial protection against tetanus toxin in
the animals. These results suggest that anti-tetanus MAbs
which inhibit attachment of the toxin to GT1b gangliosides
are more effective in the toxin neutralization in animals.
No protective ability of MAb 1F3E3 in the in vivo exper-
iment may indicate involvement of the other receptors in
the entrance of te tanus toxin to neuronal cel ls .
Surprisingly, epitope mapping of these MAbs against
HCC subdomain of fragment C revealed that only one of
6 MAbs (1F3E3) showed positive reactivity to HCC
subdomain. As HCC subdomain contains key amino acids
responsible for the binding of tetanus toxin to GT1b gan-
gliosides, the inhibitory activity of 5 other MAbs to the
gangliosides can be explained through steric hindrance of
FC region on the GT1b ganglioside binding site of the
toxin or conformational changes in GT1b binding domain
of the toxin resulting in the prevention of its binding to the
gangliosides (Yousefi et al. 2014b; Yousefi et al. 2014a;
Yousefi et al. 2016).
Analysis of the MAbs against fragment C proposed that
GD1b gangliosides might be as essential as GT1b ganglio-
sides in mediating entrance of tetanus toxin into neurons and
their blocking led to protection of mice against tetanus toxin.
MAb 51 with ability to protect against 2-fold 50% lethal dose
of tetanus toxin (2LD50), almost completely inhibited tetanus
toxin binding to GD1b gangliosides (Lukic et al. 2015).
Furthermore, 10 μg of MAb 51 resulted in complete recovery
of 100% of mice from the pathology of tetanus, when applied
2 and 6 h after tetanus toxin intoxication and 60% after 24 h of
tetanus intoxication. Interestingly, three other MAbs in this
study including MAb 33, 39, and 71, which exerted partial
protection against tetanus with the survival rates of 80%, 80%,
and 60%, respectively, partially inhibited binding of tetanus
toxin to GD1b gangliosides (almost 50–60%). Accordingly,
they were able to partially protect against tetanus toxin
challenge, following 2 and 6 h of intoxication (survival rates
between 40 and 80%). Conversely, another MAb designated
MAb 41, which completely inhibited toxin binding to GD1b
receptors, did not protect the mice from 2LD50 of tetanus
toxin, suggesting that GD1b gangliosides are not the sole re-
ceptors mediating entrance of tetanus toxin to neuronal cells
(Lukic et al. 2015).
Another line of evidence supporting the idea that at least
some of the protective epitopes of tetanus toxin are located in
fragment C comes from the studies in which recombinant or
purified native fragment C has been utilized as a vaccine can-
didate. In this regard, functionality of a subunit vaccine com-
posed of recombinant fragment C was evaluated in a gangli-
oside binding assay. Results of this functional assay showed
that binding affinity of recombinant fragment C to GT1b gan-
gliosides was as strong as that of tetanus toxin. Thereafter,
efficacy of two doses of fragment C-vaccine was compared
to the equivalent doses of toxoid-vaccine. The results showed
that while vaccination with the equivalent doses of toxoid
resulted in a partial protection against a subcutaneous chal-
lenge of 100,000-fold of LD50 in the mice, fragment C-
vaccine provided 100% survival rate in all vaccinated animals.
Accordingly, more elevated levels of anti-fragment C and anti-
toxoid antibodies titer were observed in fragment C- vaccinat-
ed mice. Furthermore, the titer of neutralizing antibodies
against fragment C in vaccinated mice was higher than those
in the mice receiving toxoid-vaccine (≥ 0.25 IU/ml for frag-
ment C- vaccinated mice compared with ≤ 0.125 IU/ml for
toxoid-vaccinated mice). Results of a detailed study on eval-
uating efficacy of the recombinant fragment C vaccine using
alhydrogel adjuvant revealed that a single injection of 1 μg of
fragment C-vaccine was able to provide complete protection
against 1000 LD50 of the toxin, while two injections of as few
as 0.04 μg of the vaccine resulted in almost complete protec-
tion of the mice against 10,000 and 100,000 LD50 of the
toxin. Furthermore, the serum anti-tetanus antibody of frag-
ment C-vaccinated mice inhibited binding of fragment C and
toxin to GT1b gangliosides even more effectively than that of
toxoid-vaccinated mice, indicating that the neutralizing capac-
ity of fragment C-vaccine was associated to its potential in
eliciting antibodies with ability to block binding of fragment
C to its gangliosides receptors (Yu et al. 2011; Fairweather
et al. 1987).
Another study has shown that a vaccine composed of frag-
ment C domain alone would be as efficient as the vaccine
consisted of fragment C and other domains of the toxin in
providing protection against tetanus toxin. Fairweather et al.
evaluated immune response and protective capacity of two
tetanus toxin fragments including purified fragment C and a
63 kDa recombinant protein consisting of all 451 residues of
fragment C as well as 121 residues of fragment B (residues
743 to 1314). Their results showed that immunization of mice
with an equal level of purified fragment C or 63 kDa
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recombinant protein elicited a comparable level of antibody
and protection indicating that fragment C domain alone would
be able to provide protection against tetanus toxin
(Fairweather et al. 1987).
It has been demonstrated that some derivatives of fragment
C of tetanus toxin (TetC), including TetC1-451, TetC1-271,
TetC1-180, and TetC80-451 could induce protective immuni-
ty in the mice (Figueiredo et al. 1995). This suggests that a
subunit vaccine spanning TetC80-180 of tetanus toxin might
provide protection against tetanus, although its protective abil-
ity against tetanus in human remained to be evaluated. To
investigate the mechanism by which TetC1-451, TetC1-271,
TetC1-180, and TetC80-451 provide protection, the binding
properties of these recombinant fragments to primary neurons
were evaluated. While TetC1-451 and TetC80-451 bound to
the primary neurons, TetC1-271 and TetC1-180 were not able
to bind to neurons, suggesting that protective effect of anti-
bodies against TetC1-451 and TetC80-451 was probably me-
diated through inhibition of the binding of toxin to its recep-
tors (Figueiredo et al. 1995). It seems that TetC80-271 con-
tains a critical region which is necessary for binding of frag-
ment C to its receptor. The other recombinant fragments in-
cluding TetC1-92 and TetC391-451 were inactive in this bind-
ing assay. Recombinant fragment TetC1-405, which lacks 46
carboxy-terminal residues of fragment C, showed poor ability
in providing protection against tetanus. This is probably relat-
ed to its poor solubility especially that immunization with this
derivative induced low level of specific antibody (Figueiredo
et al. 1995).
Protective Anti-Tetanus MAbs Against Regions Other
Than Fragment C
It has been shown that anti-tetanus MAbs directed against
regions other than fragment C of the toxin are also able to
neutralize tetanus toxin. Although the exact mechanisms of
their neutralizing capacity is not clear, it is possible that one
or more of the following steps is prevented by these MAbs
(Volk et al. 1984): (1) transport of the toxin across the cell
membrane; (2) retrograde transport of the toxin along the
nerve fibers to its targets; (3) blocking the action of the toxin
on its target. Additionally, it is possible that binding of these
MAbs to the toxin lead to a conformational change on the
receptor binding domain of the toxin and subsequently pre-
vent binding of tetanus toxin to its receptor (Volk et al. 1984).
Furthermore, it has been suggested that the other regions of
the toxin except fragment C might contribute to its binding to
the neuronal membrane and consequently their blocking led to
the inhibition of tetanus toxin binding to its receptors (Helting
et al. 1977; Pellizzari et al. 1999; Blum et al. 2014). One of the
evidences comes from a study in which a significantly higher
concentration of fragment C than the whole toxin was required
to achieve the same effects of the toxin in the binding to the
gangliosides, neural membranes, and retrograde axonal trans-
port (Helting et al. 1977). Accordingly, fragment C did not
inhibit retrograde axonal transport of whole toxin (Pellizzari
et al. 1999).
Results of a study showed that a large proportion of neu-
tralizing MAbs generated against tetanus toxoid (almost 67%
of all generated MAbs) were directed against distinct epitopes
of fragment B. These MAbs were able to protect the mice
from a L+/1000 dose of the toxin. Interestingly, when recom-
binant Ιbc fragment which contains fragment A and B of the
toxin was used to immunize mice against tetanus, none of the
isolated MAbs could protect the mice from the L+/1000 dose
of the toxin, suggesting that three-dimensional structure of
isolated fragment Ιbc may slightly differ from that of the intact
molecule. Therefore, generated MAbs against epitopes of
fragment Ιbc would not be able to bind to antigenic determi-
nants of this fragment in the intact molecule and consequently
neutralize its toxic effect (Volk et al. 1984). In another study,
50% of generated MAbs with neutralizing capacity against
tetanus toxin were directed against fragment B. These includ-
ed MAbs G1, G3, and G6 which were able to protect the mice
from 20MLD of toxin in doses as minimal as 0.89, 2.8 and
0.028 μg, respectively (neutralizing potency of these MAbs
was 1, 0.3, and 30 IU/70 μg, respectively). In addition, a
curative effect was observed following an IV injection of
0.03 IU of MAbs G2 and G6 within 6-10 h of intoxication
of mice with 4MLD of toxin (Matsuda et al. 1992).
In addition to neutralizing MAbs directed against fragment
B, protective MAbs against fragment A of the toxin were also
identified. Using a neutralization inhibition test, Hardgree
et al. estimated that about 25% of total neutralizing antibodies
in human tetanus immunoglobulin (TIG) are directed against
fragment A in light chain of the toxin (Lin et al. 1985). Lang
et al. demonstrated that neutralizing capacity of TIG was pri-
marily conferred by anti-fragment A antibodies, since protec-
tive capacity of TIG was completely abolished by addition of
2 μg fragment A; however, absorption of TIGwith eight times
higher concentration of fragment C than that of fragment A
had no significant effect on its potency (Lang et al. 1993).
They also demonstrated that a majority of anti-tetanus MAbs
produced by EBV transformation of human B cells were di-
rected against epitopes located on fragment A in light chain of
the toxin (> 90%) and 16% of clones exhibited partial neutral-
izing activity resulted in a delay in the death of the mice
intoxicated with 45MLD of toxin (neutralizing activity of an-
tibodies was in the range of 2.4 to > 5.5 IU/100 μg) (Lang
et al. 1993). Furthermore, one of theseMAbs designated ST15
was able to provide partial protection against higher levels of
the toxin (450MLD). Since all theMAbs belonged to the same
sub-class (IgG1) and no correlation between their affinities
and neutralizing activities was observed, the differences in
neutralizing activity between these MAbs are probably related
to the targeted epitopes localized on fragment A. This suggests
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that some epitopes of fragment A are much more crucial than
the others in elicitation of protective antibodies against tetanus
(Lang et al. 1993). Interestingly, the only MAb which was
able to completely give protection against tetanus recognized
an epitope located in both fragments C and A, suggesting that
there might be a shared epitope between fragments C and A of
the toxin (Lang et al. 1993). The estimated neutralizing activ-
ity of ST15 MAb was ranged between > 5.5 and 13.2 IU/
100 μg IgG for 45MLD and 450MLD of toxin, respectively
(Lang et al. 1993). The concept of presence of a shared epitope
between fragment C in heavy chain and fragment A in light
chain of tetanus toxin was proposed for the first time by
Scrivner et al. (Scrivner et al. 1987).
The other reported protective MAb against fragment A,
MAb-G4, was able to protect the mice against 20 MLD of
tetanus toxin at a minimum dose of 2.8 μg (equivalent to a
potency of 0.3 IU/70 μg of IgG). An IV dose of 0.03 IU of
MAb-G4 suppressed the progression of tetanus symptoms
following 10 h of mice intoxication with 4MLD of the toxin.
The MAb treatment within 18–24 h of intoxication, only de-
layed the symptoms’ progression and finally death of the mice
was occurred (Matsuda et al. 1992). It seems that protective
epitopes of fragment A are distinct from the epitopes retaining
its enzymatic activity. Vaccination with two doses of a recom-
binant form of fragment A incorporating a Glu-234 to Ala
mutation in active site of the enzyme, which leads to abolish-
ment of enzymatic activity of fragment A, resulted in com-
plete protection of the mice against LD50 of tetanus toxin, the
same as the recombinant unmutated form of fragment A
(Figueiredo et al. 1995).
In addition to protective MAbs recognizing epitopes locat-
ed on fragment C, B, or A, there are protective MAbs which
reacted neither with the isolated epitopes of heavy chain nor
with those of light chain. This suggests that targeted epitopes
of these MAbs are conformational epitopes which are
destroyed upon isolation of heavy and light chains of the toxin
(Arunachalam et al. 1992).
It is notable that the epitope mapping of a neutralizing
MAb may not mechanistically explain neutralizing capacities
of the MAb (Fig. 1), since its neutralizing capacity might
result from the following: (1) the steric hindrance of the Fc
region of MAbs on the receptor binding site of the toxin upon
binding of MAbs to the targeted epitope (Fig. 2c and d) or (2)
conformational change of the receptor binding site of the toxin
after binding of MAb to the toxin, which might lead to
abolished or reduced binding of toxin to its receptors (Fig.
2e). The direct evidence for this phenomenon comes from a
study in which 4 of 5 single-chain variable fragments (scFvs)
clones directed against HCN sub-domain of fragment C were
able to reduce binding of fragment C to gangliosides; there-
fore, in addition to scFvs against HCC, which is responsible
for the binding of fragment C to its receptor, scFvs against
HCN sub-domain could be protective (Yousefi et al. 2014b).
Epitope mapping of aMAb,MAb 51, with different fragments
of tetanus toxin in a western blot analysis showed that this
MAb can recognize an epitope in fragment A of the toxin.
This finding is in sharp contrast with the ability of MAb 51
in complete inhibition of tetanus toxin binding to GD1b gan-
gliosides, since the binding properties of tetanus toxin are
attributed to fragment C, which is located on the heavy chain.
These findings can be explained through the steric hindrance
of intact antibody on GD1b ganglioside-binding site of the
toxin or alternatively a conformational change on GD1b
ganglioside-binding site of the toxin upon its binding to the
toxin (Lukic et al. 2015).
Results of our study showed that neither Fab nor (Fab
′)2 fragments of 3 MAbs including 1F2C2, 1F3E3, and
2C9B6, either individually or in combination, were able
to protect mice against 10MLD of tetanus toxin even at
10 μg. However, 0.5 μg of 1F2C2, 2.5 μg of 2C9B6, and
0.25 μg of each antibody in the combination of 1F2C2 and
1F3E3 was able to completely protect the animals. The
fact that Fab and (Fab′)2 fragments of polyclonal anti-
tetanus immunoglobulin were able to fully protect the
mice against 10MLD of toxin, similar to their intact anti-
body suggests that loss of protective activity of our MAbs’
fragments is not directly attributed to their Fc region.
Steric hindrance of Fc region and/or conformational
change of the receptor binding site of the toxin by Fc
regions may explain toxin neutralization by the MAbs
(unpublished data).
Synergistic Protective Effects of a Combination
of Anti-Tetanus Monoclonal Antibodies
Polyclonal pool of human anti-tetanus immunoglobulin con-
tains antibodies directed against different epitopes of tetanus
toxin, but only a small fraction of the antibodies are capable of
neutralizing tetanus toxin. Replacement of human polyclonal
anti-tetanus immunoglobulin with anti-tetanus MAbs is feasi-
ble only if one or a limited number of anti-tetanusMAbs could
confer protection at a level comparable to the human poly-
clonal anti-tetanus immunoglobulin. So far, a few MAbs have
been reported which were individually able to confer a pro-
tective activity similar or higher than that of human polyclonal
anti-tetanus immunoglobulin (Luo et al. 2012). It has been
shown that a combination of two or more MAbs may syner-
gistically augment the neutralizing activity against tetanus
toxin compared to a single MAb. The synergism might occur
between two or more non-neutralizing MAbs which are indi-
vidually unable to protect against tetanus toxin. Indeed, utiliz-
ing a combination of these non-neutralizingMAbs was able to
provide protection against tetanus toxin challenge. Ziegler-
heitbrock et al. observed that while none of the generated
antibodies against fragments B and C located on heavy and
light chains of the toxin, respectively, was individually able to
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protect the mice against tetanus; however, a combination
consisted of anti-fragment B and anti-fragment C MAbs
protected the mice against 7 lethal dose of the toxin (Ziegler-
Heitbrock et al. 1986). Synergisms may also occur between
two or more MAbs with neutralizing ability. Matsuda et al.
showed that neutralizing capacity of a combination of three or
five MAbs (43 IU/100 μg IgG), is 10-fold higher than that of
the individual MAbs (4.3 IU/100 μg IgG). Furthermore, the
protective activity of a combination of theseMAbs was higher
than that of the human polyclonal anti-tetanus immunoglobu-
lin (43 IU/100 μg IgG for MAbs versus 33 IU/100 μg IgG for
polyclonal anti-tetanus immunoglobulin). Additionally, these
MAbs recognized epitopes located on different domains of
tetanus toxin including fragment B, C in heavy chain and
fragment A in light chain (Kamei et al. 1990).
Volk et al. clearly demonstrated that various combinations
of MAbs may induce synergistic effects. They showed that a
mixture composed of eight MAbs obtained from the spleen of
mice immunized with fragment C, provided protection against
tetanus in the mice at a concentration of 0.32 μg/ml for each
antibody, while none of the individual MAbs were able to
provide protection except one MAb, which neutralized the
toxin at the concentration of 3.2 μg/ml. Furthermore, while
none of 5 MAbs obtained from fragment B-immunized mice
was protective, a mixture consisting of all 5 MAbs provided
protection. The total required amount of neutralizing MAbs
for toxin neutralization was reduced from 0.32 μg/ml or
3.2 μg/ml of a single MAb to 0.064 μg/ml, 0.017 μg/ml,
and 0.013 μg/ml in the combinations consisted of 2, 3, and
4 MAbs, respectively. Toxin neutralizing activity of these
mixtures was comparable to that of polyclonal immunoglob-
ulin (15 to 77 IU/mg of protein for MAbs versus 29.5 IU/mg
of protein for the polyclonal anti-tetanus antibodies). These
results may suggest that an increase in the number of MAbs
in a combination would improve the protective activity of the
MAbs (Volk et al. 1984). Furthermore, the synergy could oc-
cur among MAbs recognizing epitopes located on the same
domain of the toxin as well as those directed against different
domains including fragment A, B, or C. Results of the study
performed in our lab revealed a minimum of 1.25 μg of MAb
1F2C2 in combination with MAb 1F3E3 (1.25 μg) complete-
ly protected mice against 10 MLD of the toxin similar to the
protection obtained with 10 μg of MAb 1F2C2 alone. MAb
1F3E3 did not neutralize the toxin in vivo even at the highest
dose (10 μg). Results of competition ELISA showed that
1F2C2 and 1F3E3 recognize two distinct, but spatially or
linearly very close or overlapping epitopes located within
fragment C of tetanus toxin (Yousefi et al. 2014a; Yousefi
et al. 2014b).
The same cooperative effect was observed among MAbs
recognizing different epitopes of fragment A in the light chain.
A combination of two fragment A-specific MAbs designated
ST11 and ST15, which individually gave partial protection up
to 6 days of tetanus toxin challenge, was able to completely
Fig. 2 Prevention of tetanus toxin binding to its receptors on the neuron
by monoclonal antibodies. Tetanus toxin binds to its receptors on the
neuron (a), binding of a monoclonal antibody to the receptor binding
site of the toxin inhibits toxin’s binding to the neuron (b) steric
hindrance of the Fc region of a monoclonal antibody on the receptor
binding site of the toxin results in the prevention of tetanus toxin
binding to its receptors on the neuron (c), removing the Fc region of the
monoclonal antibody leads to the loss of its neutralizing capacity in Fab
fragment and subsequent toxin binding to its receptors (d), and
conformational change of the receptor binding site of the toxin after
binding of a monoclonal antibody to the toxin leads to the abolished
binding of toxin to its receptors on the neuron (e)
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protect animals for more than 28 days after tetanus toxin chal-
lenge. The synergy was also observed among MAbs which
individually fully protected the mice against tetanus toxin.
The combinations consisted of MAb ST12, which individual-
ly was fully protective against tetanus toxin with a potency
value of 13.5 IU/100 μg IgG, with the other fully protective
MAbs including MAb ST15 (potency value of 10.5 IU/
100 μg IgG) or MAb ST11 (potency value of < 0.5 IU/
100 μg IgG) resulted in a significant increase in the potency
value, up to 43 IU/100 μg IgG. This value was far higher than
that of polyclonal anti-tetanus immunoglobulin, which was
0.263 IU/100 μg IgG. However, it is notable that not all com-
binations of anti-tetanus MAbs are able to fully protect the
animals against toxin challenge, as evidenced by utilization
of a combination consisted of two partial protective anti-
tetanus MAbs, MAb ST15 and MAb ST17. This combination
only gave a partial protection in the animals following tetanus
toxin challenge (Lang et al. 1993).
Three mechanisms may account for the synergistic ef-
fect of a combination of MAbs (Volk et al. 1984; Diamant
et al. 2015): (1) binding of one MAb may result in en-
hancement of the affinity of another MAb leading to a
more effective neutralization of the toxin; (2) clearance of
antibody-toxin immune-complexes is facilitated, since
larger immune-complexes which are formed by binding
of two or more MAbs to the toxin, will be removed faster
than the smaller complexes from the circulation by phago-
cytosis; (3) simultaneous binding of MAbs directed against
different functional epitopes of the toxin will result in a
significant blockade of several steps which are crucial for
cytotoxicity of tetanus toxin.
Determining Potency Value of MAbs
Replacement of current human polyclonal anti-tetanus im-
munoglobulin with a single or a combination of MAbs is
feasible only if the MAbs or their combination confer pro-
tection against tetanus with a potency comparable to that
of the polyclonal pool. However, determining potency val-
ue of MAbs by the standard method is questionable.
Classically, the potency of an anti-tetanus preparation is
determined by comparing the quantity of antibody neces-
sary to protect mice against paralysis or death induced by
a fixed quantity of tetanus toxin in a limited time (4 days),
with the quantity of a reference preparation, which is a
human polyclonal tetanus immunoglobulin that gives the
same level of protection (Council of Europe 2010).
It has been shown that the kinetic pattern of dose-response
of MAbs is different from that of the human polyclonal anti-
tetanus antibodies. Ahnert-Hilger et al. reported that a mouse
polyclonal anti-tetanus antibody irreversibly neutralized teta-
nus toxin in a dose-dependent manner within 4 days, while a
mouse MAb was only able to delay the death of the animals
(more than 4 days) and all the animals died at the end of the
experiment (Ahnert-higer et al. 1983). The same phenomenon
which is designated “delayed intoxication” was observed by
Matusuda et al. They showed that using the MAbs in a dose
below the minimum survival dose, resulted in a delay in the
death of the mice intoxicated with tetanus toxin and finally all
the animals died by the end of the study (Matsuda et al. 1992).
Comparison of potency values of the MAbs using the stan-
dard method with the method in which the treated mice were
monitored for 20 days demonstrated an overestimation in the
potency value of the MAbs between 1- and 30-fold (Matsuda
et al. 1992). These findings indicate that the standard method
for determining potency value of a polyclonal anti-tetanus
immunoglobulin preparation with the observation period of
4 days is not applicable to the MAbs and treated animals must
be monitored for much longer time (Matsuda et al. 1992).
Accordingly, potency of the anti-tetanus MAbs should be de-
termined based on a minimum survival dose which is required
for protection of the animals against a fixed amount of tetanus
toxin for at least 20 days (Matsuda et al. 1992).
Protective Epitopes of Tetanus Toxin as a Vaccine
Candidate
Monoclonal antibodies are useful tools in identifying immu-
nogenic and protective epitopes of the toxin for development
of epitope-based vaccines. In order to identify the immuno-
genic epitopes located on the carboxyl terminal region of tet-
anus toxin (TTC), which is responsible for the binding of
toxin to its receptors, various anti-tetanus MAbs were gener-
ated by Luo et al. and their neutralizing capacities were inves-
tigated. The highest level of protection against L+/10 dose of
toxin was obtained with MAb 5C4. It was the only anti-
fragment C MAb which was capable of blocking the binding
of recombinant fragment C to GT1b gangliosides. Afterwards,
epitope mapping of MAb 5C4 was performed using various
recombinant derivatives of fragment C including TTC(amino
acid (aa) 865–1315), TC1(aa 865–975), TC2(aa 967–1154), TC3(aa
1155–1315), TC4(aa 1118–1315), TC5(aa 1042–1171), and TC6(aa
1172–1315). MAb 5C4 recognized TTC(865–1315), TC3(1155–
1315), TC4(1118–1315), and TC5(1042–1171), but did not bind to
TC1(865–975), TC2(967–1154), and TC6(1172–1315). These results
indicated that the targeted epitope of 5C4 is located in a region
spanning residues Lys1155 to Val1171 (TC(aa 1155–1171)).
Thereafter, a peptide spanning Lys1155 to Val1171 of tetanus
toxin was synthesized and conjugated with immunogenic car-
rier protein keyhole limpet hemocyanin (KLH) and then tested
as a peptide-based vaccine against tetanus. According to the
results, 100 μg of TC(aa 1155–1171)-KLH in immunized mice
led to 80% protection against a subsequent challenge with
100% lethal dose of the toxin (LD100%). Vaccination with
100 μg of recombinant fragment C and tetanus toxoid resulted
in 100% protection of the mice. Accordingly, less titer of anti-
Neurotox Res (2020) 37:239–249 247
TC(1155–1171), anti-fragment C, and anti-toxin antibodies in
TC(1155–1171)-KLH immunized mice were generated com-
pared with the mice that have been immunized with recombi-
nant fragment C or the toxoid. It is notable that 80% protection
against the tetanus toxin is not ideal, but it is acceptable for an
epitope-based vaccine. Six otherMAbs generated in this study
also afforded protection against tetanus in the animals, with
neutralizing activities ranged from 12.5 to 15.6 IU/mg, which
were higher than that of the standard human polyclonal teta-
nus immunoglobulin (1.5 IU/mg). Their epitope mapping
demonstrated that while three of these MAbs, including
3A6, 1A12, and 1H4 recognized fragment C, none of them
were able to abolish binding of fragment C to GT1b
gangliosides.This suggests that other receptors except GT1b
gangliosides might be involved in binding of tetanus toxin to
the neurons. It is also likely that binding of MAbs to the toxin
leads to formation of immune-complexes which are removed
from the circulation by Fc-receptor-mediated phagocytosis
(Luo et al. 2012). In another study, efficacy of a fragment C-
vaccine was compared to the equivalent dose of toxoid-vac-
cine. The fragment C-vaccine resulted in the complete protec-
tion of the vaccinated animals, while toxoid-vaccine only pro-
vided a partial protection against a subcutaneous challenge of
100,000-fold of LD50 in the animals (Yu et al. 2011;
Fairweather et al. 1987). Fairweather and colleagues also
showed that a vaccine consisted of the purified fragment C
alone was as efficient as a vaccine composed of the whole
recombinant fragment C together with 121 residues of frag-
ment B (residues 743 to 1314) in eliciting a comparable level
of antibody and protection against tetanus toxin (Fairweather
et al. 1987). Results from another study showed that some
derivatives of fragment C (TetC), including TetC1-451,
TetC1-271, TetC1-180, and TetC80-451 were able to protect
the animals against tetanus toxin challenge (Figueiredo et al.
1995) suggesting that a subunit vaccine spanning TetC80-180
of tetanus toxin might provide protection against tetanus.
Conclusion
Passive immunotherapy of tetanus with human polyclonal anti-
tetanus immunoglobulin hasmany disadvantages including high
cost, lot-to-lot heterogeneity, and the adverse reactions to the
plasma proteins. Therefore, anti-tetanus MAbs which lack these
drawbacks and show protective capacity against tetanus toxin
might be considered as an alternative for passive immunothera-
py against tetanus. Epitope mapping of MAbs with protective
capacity against tetanus toxin has shown that protective epitopes
of tetanus toxin are predominantly located on fragment C; nev-
ertheless, the other two functional domains of the toxin includ-
ing fragment A on the light chain and fragment B on the heavy
chainmay display neutralizing epitopes. Furthermore, utilization
of a combination of anti-tetanus MAbs may dramatically
increase the protective activity of the MAbs leading to a more
effective immunotherapeutic activity. A cocktail of such MAbs
may prove to be more effective and suitable than the currently
available polyclonal anti-tetanus toxin preparations.
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